Raoul S. Concepcion, MD, FACS, Urology Associates P.C., Nashville, Tennessee, discusses what combinations of immunotherapy for prostate cancer treatment are most promising.

Interview produced by Prostatepedia

Keywords: combination immuonotherapy, enzalutamide, abiraterone, Provenge, Radium 223, prostate cancer

Summary:

In 2017, immunotherapy has been a popular approach for treating all tumor types. However, in this video, Dr. Concepcion explains specific recent advances in using immunotherapy for prostate cancer. He also discusses one of the toughest questions facing urologists today – can we combine immunotherapeutic agents with other treatments?  Since the only FDA approved immunotherapy, Sipuleucel-T, or PROVENGE, won’t attack androgen receptors, can we combine them with androgen excess inhibitors, such as abiraterone or enzalutamide? Can we combine immunotherapy with Radium-223, or Xofigo? Dr. Concepcion gives us his thoughts on the matter.

Dr. Concepcion further discusses combination treatments and the topic of using immunotherapy for prostate cancer in his lecture What’s New in Immunotherapy?